Drug Trial Radar · NCT05965700
NVG-291 in Spinal Cord Injury Subjects
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 8, 2023
Primary completion
Dec 31, 2025
Study completion Jan 21, 2026
Sponsor
- Lead sponsor
- NervGen PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Conditions
- Spinal Cord Injuries
- Chronic Spinal Cord Injury
- Subacute Spinal Cord Injury
Interventions
NVG-291Drug
A once daily injection
Placebo InjectionDrug
A once daily injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- ElectrophysiologicalTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shirley Ryan AbilityLab
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.